Paul Dowling1, David J Hughes2, Anne Marie Larkin3, Justine Meiller3, Michael Henry3, Paula Meleady3, Vincent Lynch3, Barbara Pardini4, Alessio Naccarati4, Miroslav Levy5, Pavel Vodicka6, Paul Neary7, Martin Clynes3. 1. Department of Biology, National University of Ireland, Maynooth, Maynooth, Co. Kildare, Ireland; National Institute for Cellular Biotechnology, Dublin City University, Glasnevin, Dublin 9, Ireland. Electronic address: paul.dowling@nuim.ie. 2. Department of Physiology and Medical Physics and Centre for Systems Medicine, Royal College of Surgeons in Ireland, Dublin 2, Ireland. 3. National Institute for Cellular Biotechnology, Dublin City University, Glasnevin, Dublin 9, Ireland. 4. Human Genetics Foundation, Turin, Italy. 5. 1st Medical Faculty of Charles University and Thomayer University Hospital, Prague, Czech Republic. 6. Institute of Experimental Medicine, Academy of Sciences of the Czech Republic, Prague, Czech Republic; Institute of Biology and Medical Genetics, 1st Medical Faculty, Charles University, Prage, Czech Republic. 7. Department of Colorectal Surgery, AMNCH Hospital, Dublin 24, Ireland.
Abstract
BACKGROUND: Colorectal cancer (CRC), a heterogeneous disease that is common in both men and women, continues to be one of the predominant cancers worldwide. Lifestyle, diet, environmental factors and gene defects all contribute towards CRC development risk. Therefore, the identification of novel biomarkers to aid in the management of CRC is crucial. The aim of the present study was to identify candidate biomarkers for CRC, and to develop a better understanding of their role in tumourogenesis. METHODS: In this study, both plasma and tissue samples from patients diagnosed with CRC, together with non-malignant and normal controls were examined using mass spectrometry based proteomics and metabolomics approaches. RESULTS: It was established that the level of several biomolecules, including serotonin, gamma enolase, pyruvate kinase and members of the 14-3-3 family of proteins, showed statistically significant changes when comparing malignant versus non-malignant patient samples, with a distinct pattern emerging mirroring cancer cell energy production. CONCLUSION: The diagnosis and management of CRC could be enhanced by the discovery and validation of new candidate biomarkers, as found in this study, aimed at facilitating early detection and/or patient stratification together with providing information on the complex behaviour of cancer cells.
BACKGROUND:Colorectal cancer (CRC), a heterogeneous disease that is common in both men and women, continues to be one of the predominant cancers worldwide. Lifestyle, diet, environmental factors and gene defects all contribute towards CRC development risk. Therefore, the identification of novel biomarkers to aid in the management of CRC is crucial. The aim of the present study was to identify candidate biomarkers for CRC, and to develop a better understanding of their role in tumourogenesis. METHODS: In this study, both plasma and tissue samples from patients diagnosed with CRC, together with non-malignant and normal controls were examined using mass spectrometry based proteomics and metabolomics approaches. RESULTS: It was established that the level of several biomolecules, including serotonin, gamma enolase, pyruvate kinase and members of the 14-3-3 family of proteins, showed statistically significant changes when comparing malignant versus non-malignant patient samples, with a distinct pattern emerging mirroring cancer cell energy production. CONCLUSION: The diagnosis and management of CRC could be enhanced by the discovery and validation of new candidate biomarkers, as found in this study, aimed at facilitating early detection and/or patient stratification together with providing information on the complex behaviour of cancer cells.
Authors: Paul Dowling; Benvon Moran; Edel McAuley; Paula Meleady; Michael Henry; Martin Clynes; Mairin McMenamin; Niamh Leonard; Mary Monks; Bairbre Wynne; Patrick Ormond; Annemarie Larkin Journal: Oncol Lett Date: 2016-09-07 Impact factor: 2.967
Authors: Fan Zhang; Yuanyuan Zhang; Weiwei Zhao; Kui Deng; Zhuozhong Wang; Chunyan Yang; Libing Ma; Margarita S Openkova; Yan Hou; Kang Li Journal: Oncotarget Date: 2017-05-23
Authors: Nikos Papadimitriou; Marc J Gunter; Neil Murphy; Audrey Gicquiau; David Achaintre; Stefanie Brezina; Tanja Gumpenberger; Andreas Baierl; Jennifer Ose; Anne J M R Geijsen; Eline H van Roekel; Andrea Gsur; Biljana Gigic; Nina Habermann; Cornelia M Ulrich; Ellen Kampman; Matty P Weijenberg; Per Magne Ueland; Rudolf Kaaks; Verena Katzke; Vittorio Krogh; Bas Bueno-de-Mesquita; Eva Ardanaz; Ruth C Travis; Matthias B Schulze; Maria-José Sánchez; Sandra M Colorado-Yohar; Elisabete Weiderpass; Augustin Scalbert; Pekka Keski-Rahkonen Journal: Int J Cancer Date: 2021-07-12 Impact factor: 7.396
Authors: Anne J M R Geijsen; Stefanie Brezina; Pekka Keski-Rahkonen; Andreas Baierl; Thomas Bachleitner-Hofmann; Michael M Bergmann; Juergen Boehm; Hermann Brenner; Jenny Chang-Claude; Fränzel J B van Duijnhoven; Biljana Gigic; Tanja Gumpenberger; Philipp Hofer; Michael Hoffmeister; Andreana N Holowatyj; Judith Karner-Hanusch; Dieuwertje E Kok; Gernot Leeb; Arve Ulvik; Nivonirina Robinot; Jennifer Ose; Anton Stift; Petra Schrotz-King; Alexis B Ulrich; Per Magne Ueland; Ellen Kampman; Augustin Scalbert; Nina Habermann; Andrea Gsur; Cornelia M Ulrich Journal: Int J Cancer Date: 2019-02-14 Impact factor: 7.396